Clinical Trial Update: A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating itolizumab in combination with corticosteroids for first-line acute graft-versus-host disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Itolizumab (Itolizumab)

Snippet

Sponsor: Equillium | Conditions: Graft Versus Host Disease, GVHD | Phase 3 | Status: TERMINATED